VI
Viracta Therapeutics, Inc.
VIRX · OTC
$0.01 +0.00% (+$0.00)
Piotroski F-Score Weak
2/9Valuation
-
N/A PEG N/A
P/E N/A
P/B N/A
Growth
-
N/A FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
-
N/A ROA N/A
ROIC N/A
Asset turnover N/A
Debt
-
N/A Int. coverage N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Stability
8 /100
Unstable Profitable years 0
Beta 0.28x
EPS volatility 673.57%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o VIRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Craig R. Jalbert
Employees
26
Headquarters
Cardiff-by-the-Sea